# Certificate of analysis

Source: https://onco.cc/terms/certificate-of-analysis/  
OnCo record `certificate-of-analysis` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A certificate of analysis reports specified test results for an identified material lot. It needs to be read with the tests, acceptance criteria and intended use.

## Summary

ICH Q7 describes certificates for active-ingredient or intermediate batches, including identity, batch details, tests, acceptance limits and results. FDA CAR T-cell guidance also discusses assessment of incoming material certificates. Requirements depend on the material and governing framework. A certificate is a lot-specific report, not independent proof of every possible property, general regulatory approval or clinical benefit. Q7 says an authentic certificate should be issued for each batch on request, give the material name, batch number and release date, list each test with its acceptance limits and numerical results, and be dated and signed by authorised quality-unit personnel (11.40 to 11.42). Q7 also allows a supplier's certificate to replace some incoming-material tests only where the manufacturer has a supplier-evaluation system and still tests identity of each batch (7.30), so a raw-material certificate is not a result for the final product. FDA's 2024 CAR T guidance says vector copy number per CAR-positive cell should be reported on the lot certificate and that supplier certificates form part of reagent qualification.

## Fields

- Kind: Term
- Last checked: 2026-11-10
- Also known as: lot certificate of analysis

## Notes

- A certificate of analysis is tied to a lot and a material. A raw-material certificate is not a final-product certificate. ICH Q7 allows a supplier's certificate to replace some incoming-material tests only where the manufacturer has a system to evaluate suppliers and still tests identity of each batch (7.30), and FDA's CAR T guidance lists certificate assessment among reagent qualification steps next to visual inspection and testing. A shared project label cannot turn a raw-material result into a final-cell result.
- Read method, result, unit, denominator and criterion together. FDA's CAR T guidance gives an example: the average vector copy number per CAR-positive cell should be reported on the lot certificate, and dividing by total cells instead includes CAR-negative cells in the denominator and lowers the reported value. A number can mean a concentration, a percentage of a defined count, or activity relative to a reference, so within specification is interpretable only once the specification and reporting method are known.
- Issuing context. ICH Q7 section 11.4 says a certificate should give the material name, grade, batch number and release date, expiry or retest date, each test with acceptance limits and numerical results, and be dated and signed by authorised quality-unit personnel. Q7 is scoped to active ingredients and intermediates, so this is a reading aid and not a required template for a final cell product.
- A certificate reports; a quality review decides. The existence of the document does not independently prove the whole review, because raw data, manufacturing records and investigations may sit elsewhere. Release is the documented disposition of the lot (see batch release).
- Viability, identity and potency answer different questions, and a certificate is not evidence of clinical effect, eligibility or lawful access. The reading rule for gaps: not reported is not zero, not failed and not passed, and a later storage or handling event is not resolved by an earlier acceptable laboratory result, which is why Q7 also dates results and gives retest dates.

## Sources

- FDA/ICH Q7: certificates of analysis, section 11.4: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-guidance-industry
- FDA: considerations for development of CAR T-cell products: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products
- FDA/ICH Q7 (September 2016): sections 7.30 and 11.4: https://www.fda.gov/files/drugs/published/Q7-Good-Manufacturing-Practice-Guidance-for-Active-Pharmaceutical-Ingredients-Guidance-for-Industry.pdf

## Connected records

- terms: [Chemistry, manufacturing and controls](https://onco.cc/terms/chemistry-manufacturing-controls/), [Comparability after manufacturing changes](https://onco.cc/terms/manufacturing-process-comparability/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Vein-to-vein time and manufacturing slots](https://onco.cc/terms/vein-to-vein-time/)
- technologies: [Cell-therapy release and potency testing](https://onco.cc/technologies/cell-therapy-release-testing/)

---
JSON: https://onco.cc/api/v1/entities/certificate-of-analysis.json